{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:03:15Z","timestamp":1777010595776,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s12020-014-0283-1","type":"journal-article","created":{"date-parts":[[2014,5,30]],"date-time":"2014-05-30T23:29:59Z","timestamp":1401492599000},"page":"241-247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Intraorbital injection of rituximab versus high dose of systemic glucocorticoids in the treatment of thyroid-associated orbitopathy"],"prefix":"10.1007","volume":"48","author":[{"given":"Gustavo","family":"Savino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Mandar\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Gari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remo","family":"Battendieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore Maria","family":"Corsello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Pontecorvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,1]]},"reference":[{"key":"283_CR1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12020-012-9607-1","volume":"41","author":"ML Tanda","year":"2012","unstructured":"M.L. Tanda, E. Piantanida, L. Bartalena, Treating Graves\u2019 orbitopathy: where are we? Endocrine 41, 167\u2013168 (2012)","journal-title":"Endocrine"},{"key":"283_CR2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s12020-011-9559-x","volume":"41","author":"A Bellis De","year":"2012","unstructured":"A. De Bellis, G. Conzo, G. Cennamo, E. Pane, G. Bellastella, C. Colella, A.D. Iacovo, V.A. Paglionico, A.A. Sinisi, J.R. Wall, A. Bizzarro, A. Bellastella, Time course of Graves\u2019 ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2\u00a0year longitudinal study. Endocrine 41, 320\u2013326 (2012)","journal-title":"Endocrine"},{"key":"283_CR3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1046\/j.1365-2265.1999.00843.x","volume":"51","author":"C Marcocci","year":"1999","unstructured":"C. Marcocci, G. Bruno-Bossio, L. Manetti, M.L. Tanda, P. Miccoli, P. Iacconi, M.P. Bartolomei, M. Nardi, A. Pinchera, L. Bartalena, The course of Graves\u2019 ophthalmopathy is not influenced by near total thyroidectomy: a case\u2013control study. Clin. Endocrinol. 51, 503\u2013508 (1999)","journal-title":"Clin. Endocrinol."},{"key":"283_CR4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.beem.2011.11.001","volume":"26","author":"WM Wiersinga","year":"2012","unstructured":"W.M. Wiersinga, Quality of life in Graves\u2019 ophthalmopathy. Best Pract. Res. Clin. Endocrinol. Metab. 26, 359\u2013370 (2012)","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"283_CR5","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/nrendo.2013.193","volume":"9","author":"L Bartalena","year":"2013","unstructured":"L. Bartalena, Diagnosis and management of Graves\u2019s disease: a global overview. Nat. Rev. Endocrinol. 9, 724\u2013734 (2013)","journal-title":"Nat. Rev. Endocrinol."},{"key":"283_CR6","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1089\/105072503322240004","volume":"13","author":"M Moleti","year":"2003","unstructured":"M. Moleti, F. Mattina, I. Salamone, M.A. Violi, C. Nucera, S. Baldari, M.G. Lo Schiavo, C. Regalbuto, F. Trimarchi, F. Vermiglio, Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of graves\u2019 ophthalmopathy. Thyroid 13, 653\u2013658 (2003)","journal-title":"Thyroid"},{"key":"283_CR7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","volume":"158","author":"L Bartalena","year":"2008","unstructured":"L. Bartalena, L. Baldeschi, A. Dickinson, A. Eckstein, P. Kendall-Taylor et al., Consensus statement of the European Group on Graves\u2019 orbitopathy (EUGOGO) on management of GO. Eur. J. Endocrinol. 158, 273\u2013285 (2008)","journal-title":"Eur. J. Endocrinol."},{"key":"283_CR8","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1530\/eje.1.02124","volume":"154","author":"T Watt","year":"2006","unstructured":"T. Watt, M. Groenvold, A.K. Rasmussen, S.J. Bonnema, L. Heged\u00fcs, J.B. Bjorner, U. Feldt-Rasmussen, Quality of life in patients with benign thyroid disorders. A review. Eur. J. Endocrinol. 154, 501\u2013510 (2006)","journal-title":"Eur. J. Endocrinol."},{"key":"283_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2265.2010.03806.x","volume":"74","author":"L Heged\u00fcs","year":"2011","unstructured":"L. Heged\u00fcs, T.J. Smith, R.S. Douglas, C.H. Nielsen, Targeted biological therapies for Graves disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with rituximab. Clin. Endocrinol. 74, 1\u20138 (2011)","journal-title":"Clin. Endocrinol."},{"key":"283_CR10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.survophthal.2012.10.006","volume":"58","author":"S Shen","year":"2013","unstructured":"S. Shen, A. Chan, P.P. Sfikakis, A.L. Hsiu-Ling, E.T. Detorakis et al., B-cell targeted therapy with rituximab for thyroid eye disease: closer to the clinic. Surv. Ophthalmol. 58, 252\u2013265 (2013)","journal-title":"Surv. Ophthalmol."},{"key":"283_CR11","author":"N Minakaran","year":"2013","unstructured":"N. Minakaran, D.G. Ezra, Rituximab for thyroid-associated ophthalmopathy. Cochrane Database Syst. Rev. (2013). doi: 10.1002\/14651858","journal-title":"Cochrane Database Syst. Rev."},{"key":"283_CR12","doi-asserted-by":"crossref","first-page":"677","DOI":"10.4158\/EP09385.RA","volume":"16","author":"S Madaschi","year":"2010","unstructured":"S. Madaschi, A. Rossini, I. Formenti, V. Lampasona, S.B. Marzoli, G. Cammarata, L.S. Politi, V. Martinelli, E. Bazzigaluppi, M. Scavini, E. Bosi, R. Lanzi, Treatment of thyroid associated orbitopathy with rituximab a novel therapy for an old disease case report and literature review. Endocr. Pract. 16, 677\u2013685 (2010)","journal-title":"Endocr. Pract."},{"key":"283_CR13","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdg175","volume":"14","author":"J Boye","year":"2003","unstructured":"J. Boye, T. Elter, A. Engert, An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann. Oncol. 14, 520\u2013535 (2003)","journal-title":"Ann. Oncol."},{"issue":"Suppl 3","key":"283_CR14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/ar1739","volume":"7","author":"A Mohrbacher","year":"2005","unstructured":"A. Mohrbacher, B cell non-Hodgkin\u2019s lymphoma: rituximab safety experience. Arthritis Res Ther 7(Suppl 3), 19\u201325 (2005)","journal-title":"Arthritis Res Ther"},{"key":"283_CR15","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00432-013-1438-9","volume":"139","author":"G Savino","year":"2013","unstructured":"G. Savino, R. Battendieri, M. Gari, M.G. Caputo, L. Laurenti, M.A. Blasi, Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections. J. Cancer Res. Clin. Oncol. 139, 1251\u20131255 (2013)","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"283_CR16","first-page":"896","volume":"31","author":"F Mu\u00f1oz-Beamud","year":"2013","unstructured":"F. Mu\u00f1oz-Beamud, D.A. Isenberg, Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. Clin. Exp. Rheumatol. 31, 896\u2013903 (2013)","journal-title":"Clin. Exp. Rheumatol."},{"key":"283_CR17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","volume":"65","author":"M Kasperkiewicz","year":"2011","unstructured":"M. Kasperkiewicz, I. Shimanovich, R.J. Ludwig, C. Rose, D. Zillikens, E. Schmidt, Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J. Am. Acad. Dermatol. 65, 552\u2013558 (2011)","journal-title":"J. Am. Acad. Dermatol."},{"key":"283_CR18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1001\/archopthalmol.2011.1215","volume":"130","author":"M Salvi","year":"2012","unstructured":"M. Salvi, G. Vannucchi, N. Curr\u00f2, M. Introna, S. Rossi et al., Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action. Arch. Ophthalmol. 130, 122\u2013124 (2012)","journal-title":"Arch. Ophthalmol."},{"key":"283_CR19","first-page":"173","volume":"38","author":"G Savino","year":"2013","unstructured":"G. Savino, L. Balia, D. Colucci, R. Battendieri, M. Gari, S.M. Corsello, A. Pontecorvi, A. Dickmann, Intraorbital injection of rituximab: a new approach for active thyroid-associated orbitopathy, a prospective case series. Minerva Endocrinol. 38, 173\u2013179 (2013)","journal-title":"Minerva Endocrinol."},{"key":"283_CR20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clim.2008.09.007","volume":"130","author":"D El Fassi","year":"2009","unstructured":"D. El Fassi, J.P. Banga, J.A. Gilbert, C. Padoa, L. Heged\u00fcs, C.H. Nielsen, Treatment of Graves\u2019 disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin. Immunol. 130, 252\u2013258 (2009)","journal-title":"Clin. Immunol."},{"key":"283_CR21","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1365-2249.2010.04191.x","volume":"161","author":"G Vannucchi","year":"2010","unstructured":"G. Vannucchi, I. Campi, M. Bonomi, D. Covelli, D. Dazzi et al., Rituximab treatment in patients with active Graves\u2019 orbitopathy: effects on proinflammatory and humoral immune reactions. Clin. Exp. Immunol. 161, 436\u2013443 (2010)","journal-title":"Clin. Exp. Immunol."},{"key":"283_CR22","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1002\/art.24906","volume":"60","author":"RM Fleischmann","year":"2009","unstructured":"R.M. Fleischmann, Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum. 60, 3225\u20133228 (2009)","journal-title":"Arthritis Rheum."},{"key":"283_CR23","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.arcmed.2013.09.011","volume":"44","author":"T Arredondo-Garza","year":"2013","unstructured":"T. Arredondo-Garza, A. Majluf-Cruz, J. Vela-Ojeda, I. Mariscal-Ram\u00edrez, L. Solis-Anaya et al., Peri-infusional adverse reactions to rituximab in patients with non-Hodgkin\u2019s lymphoma. Arch. Med. Res. 44, 549\u2013554 (2013)","journal-title":"Arch. Med. Res."},{"key":"283_CR24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.12659\/MSM.882034","volume":"17","author":"A Weissmann-Brenner","year":"2011","unstructured":"A. Weissmann-Brenner, B. Brenner, I. Belyaeva, M. Lahav, E. Rabizadeh, Rituximab associated neutropenia: description of three cases and an insight into the underlying pathogenesis. Med. Sci. Monit. 17, 133\u2013137 (2011)","journal-title":"Med. Sci. Monit."},{"key":"283_CR25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"M.P. Mourits, M.F. Prummel, W.M. Wiersinga, L. Koornneef, Clinical activity score as a guide in the management of patients with Grave\u2019s ophthalmopathy. Clin. Endocrinol. 47, 9\u201314 (1997)","journal-title":"Clin. Endocrinol."},{"key":"283_CR26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3341\/kjo.2010.24.2.65","volume":"24","author":"H Lee","year":"2010","unstructured":"H. Lee, H.S. Roh, J.S. Yoon, S.Y. Lee, Assessment of quality of life and depression in Korean patients with Graves\u2019 ophthalmopathy. Korean J. Ophthalmol. 24, 65\u201372 (2010)","journal-title":"Korean J. Ophthalmol."},{"key":"283_CR27","first-page":"536","volume":"63","author":"N Tello-Winniczuk","year":"2011","unstructured":"N. Tello-Winniczuk, E. D\u00edaz-Jouanen, Rituximab: a new therapeutic alternative in Grave\u2019s disease. Rev. Invest. Clin. 63, 536\u2013543 (2011)","journal-title":"Rev. Invest. Clin."},{"key":"283_CR28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/01676830903104611","volume":"28","author":"M Salvi","year":"2009","unstructured":"M. Salvi, G. Vannucchi, I. Campi, P. Beck-Peccoz, Rituximab in the treatment of thyroid eye disease: science fiction? Orbit 28, 251\u2013255 (2009)","journal-title":"Orbit"},{"key":"283_CR29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02325","volume":"156","author":"M Salvi","year":"2007","unstructured":"M. Salvi, G. Vannucchi, I. Campi, N. Curr\u00f2, D. Dazzi et al., Treatment of Graves\u2019 disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur. J. Endocrinol. 156, 33\u201340 (2007)","journal-title":"Eur. J. Endocrinol."},{"key":"283_CR30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1742-1241.2006.01004.x","volume":"61","author":"S Aktaran","year":"2007","unstructured":"S. Aktaran, E. Akarsu, I. Erbagci, M. Araz, S. Okumus, M. Kartal, Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves\u2019 ophthalmopathy. Int. J. Clin. Pract. 61, 45\u201351 (2007)","journal-title":"Int. J. Clin. Pract."},{"key":"283_CR31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-07-0558","volume":"158","author":"RJ Geest Van","year":"2008","unstructured":"R.J. Van Geest, I.V. Sasim, H.P. Koppeschaar, R. Kalmann, S.N. Stravers et al., Methylprednisolone pulse therapy for patients with moderately severe Graves\u2019 orbitopathy: a prospective, randomized, placebo-controlled study. Eur. J. Endocrinol. 158, 229\u2013237 (2008)","journal-title":"Eur. J. Endocrinol."},{"key":"283_CR32","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/thy.2006.16.709","volume":"16","author":"D El Fassi","year":"2006","unstructured":"D. El Fassi, C.H. Nielsen, H.C. Hasselbach, L. Hegedus, Treatment-resistant severe, active Graves\u2019 ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid 16, 709\u2013710 (2006)","journal-title":"Thyroid"},{"key":"283_CR33","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1530\/eje.1.02119","volume":"154","author":"M Salvi","year":"2006","unstructured":"M. Salvi, G. Vannucchi, I. Campi, S. Rossi, P. Bonara et al., Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur. J. Endocrinol. 154, 511\u2013517 (2006)","journal-title":"Eur. J. Endocrinol."},{"key":"283_CR34","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF03343835","volume":"24","author":"PE Macchia","year":"2001","unstructured":"P.E. Macchia, M. Bagattini, G. Lupoli, M. Vitale, G. Vitale, G. Fenzi, High-dose intravenous corticosteroid therapy for Graves\u2019 ophthalmopathy. J. Endocrinol. Invest. 24, 152\u2013158 (2001)","journal-title":"J. Endocrinol. Invest."},{"key":"283_CR35","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1507\/endocrj.52.735","volume":"52","author":"S Kubota","year":"2005","unstructured":"S. Kubota, H. Ohye, E. Nishihara, T. Kudo, M. Ito et al., Effect of high dose methylprednisolone pulse therapy followed by oral prednisolone administration on the production of anti TSH receptor antibodies and clinical outcome in Graves disease. Endocr. J. 52, 735\u2013741 (2005)","journal-title":"Endocr. J."},{"key":"283_CR36","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1210\/jc.2013-1804","volume":"98","author":"M Salvi","year":"2013","unstructured":"M. Salvi, G. Vannucchi, P. Beck-Peccoz, Potential utility of rituximab for Graves\u2019 orbitopathy. J. Clin. Endocrinol. Metab. 98, 4291 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"283_CR37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1542\/peds.2009-3395","volume":"126","author":"DS Ardelean","year":"2010","unstructured":"D.S. Ardelean, T. Gonska, S. Wires, E. Cutz, A. Griffiths et al., Severe ulcerative colitis after rituximab therapy. Pediatrics 126, 243\u2013246 (2010)","journal-title":"Pediatrics"},{"key":"283_CR38","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3109\/08916934.2013.838563","volume":"46","author":"S Shetty","year":"2013","unstructured":"S. Shetty, A.R. Ahmed, Preliminary analysis of mortality associated with rituximab use in autoimmune diseases. Autoimmunity 46, 487\u2013496 (2013)","journal-title":"Autoimmunity"},{"key":"283_CR39","author":"N Curr\u00f2","year":"2014","unstructured":"N. Curr\u00f2, D. Covelli, G. Vannucchi, I. Campi, G. Pirola, S. Simonetta, D. Dazzi, C. Guastella, L. Pignataro, P. Beck-Peccoz, R. Ratiglia, M. Salvi, Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy. Thyroid (2014). doi: 10.1089\/2013.0445","journal-title":"Thyroid"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-014-0283-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-014-0283-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-014-0283-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T21:56:52Z","timestamp":1559426212000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-014-0283-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["283"],"URL":"https:\/\/doi.org\/10.1007\/s12020-014-0283-1","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,1]]}}}